RxDoctor Payments Data

Richard Belkin, MD

Pulmonary Disease · Santa Barbara, CANPI 1659380178

Payments from drug & device makers

$238,701in general payments, 2019–2025

Across 881 payments — averaging $270.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$157K
  • Mannkind Corporation$48K
  • Intuitive Surgical$12K
  • Vertex$8K
  • GSK$3K
  • AstraZeneca$1K
  • plus $9K from 43 others

What the payments were for

  • Consulting fees$23,00931%
  • Speaking & faculty fees$15,33521%
  • Travel & lodging$8,72212%
  • Food & beverage$16,24522%
  • Education$10,84215%
  • Gifts$1010%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$238,701 in reported general payments places this provider in the 90th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$576,496
Medicare patients
579
Services billed
8,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrikaftaElexacaftor/Tezacaftor/Ivacaft69$1,820,498
OfevNintedanib Esylate62$809,837
Trelegy ElliptaFluticasone/Umeclidin/Vilanter402$332,638
Dupixent SyringeDupilumab71$269,416
CaystonAztreonam Lysine14$168,281
Dupixent PenDupilumab19$100,298
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr126$77,462
CreonLipase/Protease/Amylase16$64,076
EliquisApixaban65$44,021
Breo ElliptaFluticasone/Vilanterol61$31,974
XareltoRivaroxaban16$16,373
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$16,042
ColistimethateColistin (Colistimethate Na)21$13,797
Incruse ElliptaUmeclidinium Bromide19$10,658
Albuterol Sulfate HfaAlbuterol Sulfate268$10,354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
VertexTrikafta$8,034$1,820,49869 claims
Boehringer IngelheimOfev, Stiolto Respimat$895$825,87976 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$2,895$459,840626 claims
GileadCayston$37$168,28114 claims
AbbVieCreon$749$64,07616 claims
PfizerEliquis, Paxlovid$103$46,88077 claims
Johnson & JohnsonXarelto$123$16,37316 claims
AstraZenecaSymbicort$1,403$9,08423 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$19$6,58225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →